EU regulatory reforms aim to unlock medtech innovation

  • Home
  • Newsroom
  • EU regulatory reforms aim to unlock medtech innovation
EU regulatory reforms aim to unlock medtech innovation - Axcellant

EU regulatory reforms aim to unlock medtech innovation

  1. maj 30, 2025

The EU is moving forward with key upgrades to its medical device and diagnostics regulations, specifically under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).

Following years of regulatory bottlenecks, these changes are especially relevant to developers of diagnostics and Software as a Medical Device (SaMD).

At Axcellant, we help companies navigate this evolving landscape through trial design, submissions, and implementation. Greater predictability and clarity in the system open the door to faster innovation — a goal we fully support.

See how we guide medtech and diagnostics teams across the EU regulatory landscape.

Resources

Ensuring On-Time Start of a Multicenter Diagnostic Radiopharmaceutical Trial

How Axcellant stabilized isotope supply, synchronized global imaging operations, and prevented a multi-month program delay. At a Glance Study type:…

Building Market-Ready Medtech Beyond the Algorithm

At Axcellant, we work where medtech becomes real, not in headlines but in clinics, documentation, and decisions that must stand…

Axcellant partners with Prometheus MedTech.AI to accelerate AI-powered cardiac diagnostics

We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…